Oil Prices Surge Over 3% as Trump Rejects Iran Peace Response 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Saudi Aramco Q1 Profit Jumps 25% as Strait of Hormuz Crisis Reshapes Oil Exports 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Dollar Slips as Strong U.S. Jobs Data Reduces Fed Rate Cut Expectations 
K+S Raises 2026 Earnings Outlook After Strong Q1 Results 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Australia Budget 2026: Smaller Deficit Expected Amid Tax Reform Push 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
Wall Street Hits Record High as AI Chip Stocks and Strong U.S. Jobs Data Boost Markets 
Asian Stocks Rise Despite Middle East Tensions as Chipmakers Boost Markets 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
Sanofi, a pharmaceutical company headquartered in Paris, France, announced its acquisition of the American biopharmaceutical firm, Kadmon. It was revealed that the deal is worth $1.9 billion and the French drugmaker made the purchase to further strengthen the growth of its transplant business line.
Sanofi shared the news about its latest acquisition on Wednesday, Sept. 8. The firm confirmed its purchase of Kadmon Holdings just a month after buying Translate BIO, another US-based biotech company for $3.2 billion.
According to Reuters, Sanofi offered to buy Kadmon in cash at $9.50 per share which is equivalent to more or less $1.9 billion. It was mentioned that both of the firms’ boards did not oppose the deal and granted approval for the deal to proceed.
“We are transforming and simplifying our General Medicines business and have shifted our focus on differentiated core assets in key markets,” Sanofi’s executive vice president of general medicines, Olivier Charmeil, said in a press release. “We are thrilled to add Kadmon's Rezurock to our well-established transplant portfolio. Our existing scale, expertise, and relationships in transplant create an ideal platform to achieve the full potential of Rezurock, which will address the significant unmet medical needs of patients with chronic graft-versus-host disease around the world.”
On the other hand, Kadmon’s president and chief executive officer, Harlan Waksal, M.D., said that they were thrilled as Sanofi acknowledged the value of its Rezurock oral medicine for GVHD or chronic graft versus host disease, a crippling immune-mediated condition that affects many blood cancer patients who underwent bone marrow transplants.
He added that by making use of the pharmaceutical company’s global resources and well-known expertise in developing and selling new medicines, Rezurock is now in a better position for international accessibility. Kadmon’s Rezurock is a drug for the treatment of both adults and patients who are 12 years and older. It was approved by the U.S. Federal Drug Administration (FDA) in July.
Finally, with Sanofi’s acquisition of Kadmon, the said medicine will now become the French pharma company’s third drug under its transplant medicine business. This is also its third major purchase in this year alone.
